期刊
CELL CYCLE
卷 10, 期 3, 页码 380-386出版社
TAYLOR & FRANCIS INC
DOI: 10.4161/cc.10.3.14642
关键词
cisplatin; RNAi; screen; sensitivity; DDR
类别
资金
- TiPharma
- Merck Co., Inc.
Cisplatin is a widely used chemotherapeutic agent for the treatment of a variety of solid tumors. The cytotoxic mode of action of cisplatin is mediated by inducing conformational changes in DNA including intra- and interstrand crosslink adducts. Recognition of these adducts results in the activation of the DNA damage response leading to cell cycle arrest, repair and potentially, apoptosis. Despite the clinical efficacy of cisplatin, many tumors are either intrinsically resistant or acquire resistance during treatment. The identification of cisplatin drug response modulators can help us understand these resistance mechanisms, provide biomarkers for treatment strategies, or provide drug targets for combination therapy. Here we discuss functional genetic screens, including one performed by us, set up to identify genes whose inhibition results in increased sensitivity to cisplatin. In summary, the validated genes identified in these screens mainly operate in DNA damage response including nucleotide excision repair, translesion synthesis and homologous recombination.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据